Loading patent…
AssigneeGan & Lee Pharmaceuticals
InventorsJiao JIAO, Jing QIAO, Ruowei LI, Yaohui LIU, Jiaxing WANG, Zhen WANG, Han QIN, Ziyue MA, Jiao WANG, Ling ZHANG, Liming CHE, Shumiao TIAN, Ruixue WANG, Weihuan YAN, Yating JIANG
Estimating the term…
Provided are an antibody having effective neutralizing activity against RSV or an antigen-binding fragment thereof. The provided anti-RSV antibody or antigen-binding fragment thereof can be used as a drug for treating or preventing RSV infection or symptoms related to RSV infection. The provided RSV antibody, after humanization, can bind RSV-F protein with high affinity. In addition, experiments show that it is significantly better than palivizumab at providing protection against RSV challenge.
An antibody or antigen-binding fragment thereof, which specifically binds to respiratory syncytial virus fusion protein (RSV-F) and/or neutralizes respiratory syncytial virus, as determined by surface plasmon resonance, the antibody or antigen-binding fragment thereof specifically binds to RSV-F with an equilibrium dissociation constant (KD) no higher than 10−9 M.
An antibody or antigen-binding fragment thereof, which specifically binds to respiratory syncytial virus fusion protein (RSV-F) and/or neutralizes respiratory syncytial virus, the antibody or antigen-binding fragment thereof comprises:
An antibody or antigen-binding fragment thereof, which specifically binds to respiratory syncytial virus fusion protein (RSV-F) and/or neutralizes respiratory syncytial virus, the antibody or antigen-binding fragment thereof comprises:
The antibody or antigen-binding fragment thereof according to claim 11, the amino acid sequence pair of its heavy chain/light chain is selected from the group consisting of the following amino acid sequence pairs:
(canceled)
(canceled)
-22. (canceled)
-26. (canceled)
Dependencies are inferred from the claim text.